Transcode Therapeutics Inc
NASDAQ:RNAZ

Watchlist Manager
Transcode Therapeutics Inc Logo
Transcode Therapeutics Inc
NASDAQ:RNAZ
Watchlist
Price: 8.63 USD 2.62% Market Closed
Market Cap: 7.9m USD

Transcode Therapeutics Inc
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Transcode Therapeutics Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Transcode Therapeutics Inc
NASDAQ:RNAZ
EPS (Diluted)
-$1.3k
CAGR 3-Years
88%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
EPS (Diluted)
$1
CAGR 3-Years
-44%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Gilead Sciences Inc
NASDAQ:GILD
EPS (Diluted)
$6
CAGR 3-Years
35%
CAGR 5-Years
45%
CAGR 10-Years
-5%
Amgen Inc
NASDAQ:AMGN
EPS (Diluted)
$12
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
EPS (Diluted)
$14
CAGR 3-Years
4%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
EPS (Diluted)
$42
CAGR 3-Years
-4%
CAGR 5-Years
9%
CAGR 10-Years
24%
No Stocks Found

Transcode Therapeutics Inc
Glance View

Market Cap
7.2m USD
Industry
Biotechnology

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company is headquartered in Boston, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2021-04-28. The company has developed a modular, iron oxide nanoparticle-based nanocarrier system for the delivery of RNA therapeutics to tumors. The Company’s lead therapeutic candidate, TTX-MC138, targets microRNA-10b (miRNA-10b), a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include two solid tumor programs such as TTX-siPDL1, a small interfering RNA (siRNA)based modulator of programmed death-ligand 1 (PD-L1), and TTX-siLin28b, a siRNA-based inhibitor of RNA-binding protein LIN28B.

RNAZ Intrinsic Value
Not Available

See Also

What is Transcode Therapeutics Inc's EPS (Diluted)?
EPS (Diluted)
-1.3k USD

Based on the financial report for Dec 31, 2024, Transcode Therapeutics Inc's EPS (Diluted) amounts to -1.3k USD.

What is Transcode Therapeutics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
54%

Over the last year, the EPS (Diluted) growth was 99%. The average annual EPS (Diluted) growth rates for Transcode Therapeutics Inc have been 88% over the past three years , 54% over the past five years .

Back to Top